← boardnext 2027-10-30
IRWD
Ironwood Pharmaceuticals, Inc.distress 1/10 · well-funded / low risk$3.79-2%today-30% from 52w high
Pain 1
Lead: Short Bowel Syndrome
Revenue
$107M
Liquidity
$220M
Runway
—
Shares 1y
+1%
Price & events
-29.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-2.2%
1W
-1.9%
1M
-0.1%
3M
-27.6%
6M
+335.1%
1Y
-44.3%
2Y
-70.9%
5Y
-66.1%
All
Overview
- Market Cap
- $623.06M
- Enterprise Value
- $602.10M
- Volume
- 105.37K
- 52 Week Range
- $0.69 – $5.39
- Total Shares
- 164.61M
- Float Shares
- 135.05M
- Short %
- 10.77%
- % Held by Insiders
- 3.16%
- % Held by Institutions
- 99.03%
- RVOL
- 0.04x
- Beta
- 0.21
Pipeline stages · 2 programs
Apraglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IW-3300 rectal foam
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10-30 Estimated 50% readout ~2028-01-13 | Phase 3 | Apraglutide | Short Bowel Syndrome | — | active not recruiting |
| 2025-01-23 | Phase 2 | IW-3300 rectal foam | Interstitial Cystitis, Bladder Pain Syndrome | 98 | terminated |
Catalyst news & presentations · 6
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-12-18partnershipThird amendment to exclusive license agreement with Ferring, including $12.5M payment and royaltiesSEC 8-K
- September 1, 2025regulatory submissionFiled (NDA/BLA)Potential deadline to file 2024 Form 10-K if Nasdaq grants extensionSEC 8-K
- May 20, 2025regulatory submissionFiled (NDA/BLA)Deadline to submit plan to regain Nasdaq complianceSEC 8-K
- 2025-04-14fda agreementapraglutide · FDA indicates confirmatory Phase 3 needed for approvalSEC 8-K
- 2025-03-21warning letterReceived Nasdaq non-compliance notice for late 2024 Form 10-KSEC 8-K
Approved drugs (2)
- DUZALLOALLOPURINOL2017 · Discontinued
- ZURAMPICLESINURAD2015 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $6 (+68% upside) · 4 analysts
- 2026-02-26CitizensMarket Outperform
- 2026-01-05Wells FargoEqual-Weight
- 2026-01-05CitizensMarket Perform → Market Outperform
- 2025-11-11Wells FargoEqual-Weight
- 2025-04-15Wells FargoOverweight → Equal-Weight
- 2025-04-15JefferiesBuy → Hold
Competitors — Short Bowel Syndrome
Recent news
- 2026-07-22Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO - Stock Titan
- 2026-07-16Ironwood Pharmaceuticals (IRWD) Jefferies 2024 Global Healthcare Conference Summary - Quartr
- 2026-07-14Ironwood’s 30-year medical chief retires as Phase 3 trial recruits - Stock Titan
- 2026-07-14Ironwood Pharmaceuticals (IRWD) Appoints New CMO as Leadership T - GuruFocus
- 2026-07-13Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap (NASDAQ:IRWD) - Seeking Alpha
- 2026-07-10Form 4 Ironwood Pharmaceuticals Inc For: 9 July - Investing.com India
- 2026-07-09Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Canada
- 2026-07-09Ronald Silver, PFO, sells $578k in Ironwood Pharma stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.